SAN MATEO, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that target ...

STK11 loss-of-function mutations occur in ~15% of non-small cell lung cancer and drive immune evasion, rendering STK11-mutant tumors insensitive to the immune checkpoint inhibitor therapy that ...

Jade Biosciences, Inc. announced that new preclinical data on its investigational anti-APRIL monoclonal antibody, JADE101, will be presented at the 62nd European Renal Association Congress in Vienna ...

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for ...

Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings Breadth of Scientific ...

Opna Bio, a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics, announced today that it will have an oral and a poster presentation at the ...

Breadth of Scientific Evidence: The acceptance of 1 oral presentation, 5 digital oral presentations and 16 posters reflect an expanding dataset for obefazimod, including additional efficacy, safety, ...